MXPA04002624A - Vacunas glicoconjugadas para uso en poblaciones inmuno-comprometidas. - Google Patents
Vacunas glicoconjugadas para uso en poblaciones inmuno-comprometidas.Info
- Publication number
- MXPA04002624A MXPA04002624A MXPA04002624A MXPA04002624A MXPA04002624A MX PA04002624 A MXPA04002624 A MX PA04002624A MX PA04002624 A MXPA04002624 A MX PA04002624A MX PA04002624 A MXPA04002624 A MX PA04002624A MX PA04002624 A MXPA04002624 A MX PA04002624A
- Authority
- MX
- Mexico
- Prior art keywords
- antigen
- vaccine
- patients
- type
- polysaccharide
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 109
- 239000000427 antigen Substances 0.000 claims abstract description 118
- 108091007433 antigens Proteins 0.000 claims abstract description 118
- 102000036639 antigens Human genes 0.000 claims abstract description 118
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 43
- 239000005017 polysaccharide Substances 0.000 claims abstract description 43
- 230000001580 bacterial effect Effects 0.000 claims abstract description 22
- 108010015899 Glycopeptides Proteins 0.000 claims abstract description 11
- 102000002068 Glycopeptides Human genes 0.000 claims abstract description 11
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims abstract description 8
- 206010061598 Immunodeficiency Diseases 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 37
- 208000020832 chronic kidney disease Diseases 0.000 claims description 25
- 201000000523 end stage renal failure Diseases 0.000 claims description 25
- 241000194032 Enterococcus faecalis Species 0.000 claims description 14
- 241000194031 Enterococcus faecium Species 0.000 claims description 12
- 108010060123 Conjugate Vaccines Proteins 0.000 claims description 11
- 229940031670 conjugate vaccine Drugs 0.000 claims description 11
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 8
- 241000282414 Homo sapiens Species 0.000 claims description 7
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 5
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 231100000252 nontoxic Toxicity 0.000 claims description 5
- 230000003000 nontoxic effect Effects 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 4
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 4
- MBLBDJOUHNCFQT-LXGUWJNJSA-N aldehydo-N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 4
- 229930182830 galactose Natural products 0.000 claims description 4
- 210000003714 granulocyte Anatomy 0.000 claims description 4
- 150000002402 hexoses Chemical class 0.000 claims description 4
- 238000002650 immunosuppressive therapy Methods 0.000 claims description 4
- 150000004043 trisaccharides Chemical group 0.000 claims description 4
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 3
- 229920002498 Beta-glucan Polymers 0.000 claims description 3
- 206010014889 Enterococcal infections Diseases 0.000 claims description 3
- 101900161471 Pseudomonas aeruginosa Exotoxin A Proteins 0.000 claims description 3
- 230000004523 agglutinating effect Effects 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 229960000814 tetanus toxoid Drugs 0.000 claims description 3
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 2
- 239000002095 exotoxin Substances 0.000 claims description 2
- 231100000776 exotoxin Toxicity 0.000 claims description 2
- 230000007774 longterm Effects 0.000 claims description 2
- 230000002633 protecting effect Effects 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 150000004804 polysaccharides Chemical class 0.000 claims 12
- 208000017169 kidney disease Diseases 0.000 claims 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 229920001284 acidic polysaccharide Polymers 0.000 claims 1
- 150000004805 acidic polysaccharides Chemical class 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 238000012977 invasive surgical procedure Methods 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 abstract description 31
- 230000004224 protection Effects 0.000 abstract description 14
- 208000035143 Bacterial infection Diseases 0.000 abstract description 13
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 13
- 238000001356 surgical procedure Methods 0.000 abstract description 4
- 108010022457 polysaccharide peptide Proteins 0.000 abstract 1
- 208000031729 Bacteremia Diseases 0.000 description 33
- 229940068196 placebo Drugs 0.000 description 28
- 239000000902 placebo Substances 0.000 description 28
- 208000015181 infectious disease Diseases 0.000 description 27
- 238000001631 haemodialysis Methods 0.000 description 22
- 230000000322 hemodialysis Effects 0.000 description 22
- 208000028208 end stage renal disease Diseases 0.000 description 20
- 230000028993 immune response Effects 0.000 description 20
- 238000002347 injection Methods 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 238000002255 vaccination Methods 0.000 description 14
- 230000000295 complement effect Effects 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 230000034994 death Effects 0.000 description 9
- 231100000517 death Toxicity 0.000 description 9
- 230000005847 immunogenicity Effects 0.000 description 9
- 108010078791 Carrier Proteins Proteins 0.000 description 8
- 102000014914 Carrier Proteins Human genes 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 241000191940 Staphylococcus Species 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 208000037157 Azotemia Diseases 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 229960003085 meticillin Drugs 0.000 description 6
- 210000001539 phagocyte Anatomy 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 208000009852 uremia Diseases 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 206010016717 Fistula Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000003890 fistula Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000001558 permutation test Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- 102100024125 Embryonal Fyn-associated substrate Human genes 0.000 description 4
- 241000194033 Enterococcus Species 0.000 description 4
- 101001053896 Homo sapiens Embryonal Fyn-associated substrate Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 229940031416 bivalent vaccine Drugs 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 101710082714 Exotoxin A Proteins 0.000 description 3
- 206010024769 Local reaction Diseases 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 241000193998 Streptococcus pneumoniae Species 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- 230000001010 compromised effect Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 210000003622 mature neutrocyte Anatomy 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- 241000486679 Antitype Species 0.000 description 2
- 206010053555 Arthritis bacterial Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010011409 Cross infection Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 238000000729 Fisher's exact test Methods 0.000 description 2
- 241000606768 Haemophilus influenzae Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 101001050438 Homo sapiens Protein-lysine N-methyltransferase EEF2KMT Proteins 0.000 description 2
- 208000004575 Infectious Arthritis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102100023369 Protein-lysine N-methyltransferase EEF2KMT Human genes 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 206010014665 endocarditis Diseases 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 208000037916 non-allergic rhinitis Diseases 0.000 description 2
- 244000039328 opportunistic pathogen Species 0.000 description 2
- 230000000625 opsonophagocytic effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- -1 ramosa Chemical compound 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 201000001223 septic arthritis Diseases 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- NITXODYAMWZEJY-UHFFFAOYSA-N 3-(pyridin-2-yldisulfanyl)propanehydrazide Chemical compound NNC(=O)CCSSC1=CC=CC=N1 NITXODYAMWZEJY-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000570863 Brunfelsia uniflora Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 1
- 208000037041 Community-Acquired Infections Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 101100011065 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) EFM5 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010051017 Staphylococcal bacteraemia Diseases 0.000 description 1
- 241000191984 Staphylococcus haemolyticus Species 0.000 description 1
- 241000192087 Staphylococcus hominis Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010044541 Traumatic shock Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940028617 conventional vaccine Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 1
- 229940099500 cystamine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- ZNOLGFHPUIJIMJ-UHFFFAOYSA-N fenitrothion Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C(C)=C1 ZNOLGFHPUIJIMJ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940047091 other immunostimulants in atc Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940031937 polysaccharide vaccine Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 238000009021 pre-vaccination Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/955,585 US20030113350A1 (en) | 2001-09-19 | 2001-09-19 | Glycoconjugate vaccines for use in immune-compromised populations |
| PCT/US2002/029601 WO2003061558A2 (en) | 2001-09-19 | 2002-09-19 | Glycoconjugate vaccines for use in immune-compromised populations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04002624A true MXPA04002624A (es) | 2005-02-17 |
Family
ID=25497036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04002624A MXPA04002624A (es) | 2001-09-19 | 2002-09-19 | Vacunas glicoconjugadas para uso en poblaciones inmuno-comprometidas. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20030113350A1 (https=) |
| EP (1) | EP1427442A4 (https=) |
| JP (2) | JP2005515237A (https=) |
| KR (3) | KR20040070331A (https=) |
| CN (1) | CN1306958C (https=) |
| CA (1) | CA2460749C (https=) |
| EA (1) | EA006602B1 (https=) |
| MX (1) | MXPA04002624A (https=) |
| NZ (1) | NZ548453A (https=) |
| WO (1) | WO2003061558A2 (https=) |
| ZA (1) | ZA200402185B (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100217772B1 (ko) * | 1996-09-03 | 1999-09-01 | 최진호 | 조명기기의 램프 과열방지 장치 및 방법 |
| US20020092987A1 (en) * | 1998-09-05 | 2002-07-18 | Taehee Cho | Photo detect device using quantum dots and materialization method thereof |
| US6936258B1 (en) * | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
| PL229487B1 (pl) | 2002-11-12 | 2018-07-31 | Brigham & Womens Hospital Inc | Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego |
| AU2003298770A1 (en) * | 2002-12-02 | 2004-06-23 | Biosynexus Inc | Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines |
| CA2517439C (en) | 2003-03-07 | 2013-07-23 | Wyeth Holdings Corporation | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| NZ553776A (en) * | 2004-09-22 | 2010-05-28 | Glaxosmithkline Biolog Sa | Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide. |
| AU2011265368B9 (en) * | 2004-09-22 | 2012-11-29 | Biosynexus Incorporated | Immunogenic composition |
| US20060134141A1 (en) * | 2004-12-14 | 2006-06-22 | Nabi Biopharmaceuticals | Glycoconjugate vaccines containing peptidoglycan |
| WO2006076058A1 (en) * | 2005-01-10 | 2006-07-20 | Nabi Biopharmaceuticals | Method of treating staphylococcus aureus infection |
| US20060228368A1 (en) * | 2005-04-07 | 2006-10-12 | Nabi Biopharmaceuticals | Method of protecting against staphylococcal infection |
| FR2884830A1 (fr) | 2005-04-25 | 2006-10-27 | Sanofi Pasteur Sa | Procede de production de souches de staphylococcus aureus surproductrices |
| ES2372537T3 (es) * | 2005-07-29 | 2012-01-23 | The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services | Exotoxinas de pseudomonas mutadas con antigenicidad reducida. |
| EP2476433A1 (en) * | 2006-03-30 | 2012-07-18 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| FR2899110A1 (fr) * | 2006-03-31 | 2007-10-05 | Sanofi Pasteur Sa | Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus |
| GB0700136D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Process for manufacturing vaccines |
| US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
| JP5658564B2 (ja) * | 2007-08-31 | 2015-01-28 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物 |
| CN102159540B (zh) | 2008-07-21 | 2015-08-12 | 布赖汉姆妇女医院 | 与合成的β-1,6葡糖胺寡糖相关的方法和组合物 |
| WO2010014304A1 (en) * | 2008-07-29 | 2010-02-04 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
| HUE026855T2 (en) | 2009-04-03 | 2016-07-28 | Univ Chicago | Compositions and methods related to protein a (spa) variants |
| SA110310528B1 (ar) | 2009-06-22 | 2014-07-02 | Wyeth Llc | التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس |
| SG10201406432RA (en) | 2009-06-22 | 2014-11-27 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| BR112012009014B8 (pt) | 2009-09-30 | 2022-10-04 | Novartis Ag | Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica |
| HUE034251T2 (en) | 2009-10-30 | 2018-02-28 | Glaxosmithkline Biologicals Sa | Purification of staphylococcus aureus type 5 and type 8 capsular saccharides |
| EP2525800B1 (en) * | 2010-01-19 | 2018-07-04 | Universitätsklinikum Freiburg | Enterococcal cell wall components and antibacterial use thereof |
| CA2803298C (en) | 2010-07-02 | 2020-07-14 | The University Of Chicago | Compositions and methods related to protein a (spa) variants |
| CN102539704A (zh) * | 2010-12-13 | 2012-07-04 | 苏州艾杰生物科技有限公司 | 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒 |
| CN102565336A (zh) * | 2010-12-13 | 2012-07-11 | 苏州艾杰生物科技有限公司 | 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒 |
| CN102565354A (zh) * | 2010-12-13 | 2012-07-11 | 苏州艾杰生物科技有限公司 | 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒 |
| CN102539708A (zh) * | 2010-12-13 | 2012-07-04 | 苏州艾杰生物科技有限公司 | 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒 |
| CN102565332A (zh) * | 2010-12-13 | 2012-07-11 | 苏州艾杰生物科技有限公司 | 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒 |
| CN102539726A (zh) * | 2010-12-13 | 2012-07-04 | 苏州艾杰生物科技有限公司 | 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒 |
| CN102539702A (zh) * | 2010-12-13 | 2012-07-04 | 苏州艾杰生物科技有限公司 | 氨(氨离子)的测定方法与氨(氨离子)诊断/测定试剂盒 |
| US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
| US9777076B2 (en) | 2012-07-16 | 2017-10-03 | Pfizer Inc. | Saccharides and uses thereof |
| GB201310008D0 (en) | 2013-06-05 | 2013-07-17 | Glaxosmithkline Biolog Sa | Immunogenic composition for use in therapy |
| AU2015359503B2 (en) | 2014-12-10 | 2019-05-09 | Glaxosmithkline Biologicals Sa | Method of treatment |
| GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| US12397014B2 (en) | 2019-02-05 | 2025-08-26 | The Brigham And Women's Hospital, Inc. | Polysaccharide compositions for use in treating filariasis |
| US12514914B2 (en) | 2019-05-14 | 2026-01-06 | The University Of Chicago | Methods and compositions comprising Staphylococcus protein a (SpA) variants |
| EP3777884A1 (en) | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| CA3152520A1 (en) * | 2019-08-27 | 2021-03-04 | OneBioPharma, Inc. | Antimicrobial vaccine compositions |
| CN114929750B (zh) | 2019-09-13 | 2024-11-22 | 芝加哥大学 | 用于治疗葡萄球菌感染的方法和组合物 |
| US20260007731A1 (en) * | 2022-01-05 | 2026-01-08 | Bluewillow Biologics, Inc. | Intranasal polysaccharide conjugate nanomulsion vaccines and methods of using the same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747024A (en) * | 1993-03-08 | 1998-05-05 | Immunex Corporation | Vaccine adjuvant comprising interleukin-15 |
| US5770208A (en) * | 1996-09-11 | 1998-06-23 | Nabi | Staphylococcus aureus B-linked hexosamine antigen |
-
2001
- 2001-09-19 US US09/955,585 patent/US20030113350A1/en not_active Abandoned
-
2002
- 2002-09-19 EP EP02806591A patent/EP1427442A4/en not_active Ceased
- 2002-09-19 EA EA200400448A patent/EA006602B1/ru not_active IP Right Cessation
- 2002-09-19 MX MXPA04002624A patent/MXPA04002624A/es active IP Right Grant
- 2002-09-19 KR KR10-2004-7003967A patent/KR20040070331A/ko not_active Ceased
- 2002-09-19 JP JP2003561504A patent/JP2005515237A/ja active Pending
- 2002-09-19 CA CA2460749A patent/CA2460749C/en not_active Expired - Lifetime
- 2002-09-19 WO PCT/US2002/029601 patent/WO2003061558A2/en not_active Ceased
- 2002-09-19 KR KR1020087022908A patent/KR101090529B1/ko not_active Expired - Lifetime
- 2002-09-19 CN CNB028184238A patent/CN1306958C/zh not_active Expired - Lifetime
- 2002-09-19 KR KR1020107005839A patent/KR101214766B1/ko not_active Expired - Lifetime
- 2002-09-19 NZ NZ548453A patent/NZ548453A/en not_active IP Right Cessation
-
2004
- 2004-03-18 ZA ZA2004/02185A patent/ZA200402185B/en unknown
-
2006
- 2006-01-25 US US11/338,900 patent/US7449189B2/en not_active Expired - Lifetime
-
2010
- 2010-07-08 JP JP2010155473A patent/JP2010265293A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003061558A3 (en) | 2003-09-12 |
| NZ548453A (en) | 2007-07-27 |
| EP1427442A2 (en) | 2004-06-16 |
| US20030113350A1 (en) | 2003-06-19 |
| US7449189B2 (en) | 2008-11-11 |
| JP2010265293A (ja) | 2010-11-25 |
| EA200400448A1 (ru) | 2004-12-30 |
| ZA200402185B (en) | 2005-06-29 |
| CN1306958C (zh) | 2007-03-28 |
| KR101090529B1 (ko) | 2011-12-08 |
| KR20040070331A (ko) | 2004-08-07 |
| CA2460749C (en) | 2012-10-23 |
| CA2460749A1 (en) | 2003-07-31 |
| WO2003061558A9 (en) | 2004-06-10 |
| KR20080089527A (ko) | 2008-10-06 |
| KR20100044265A (ko) | 2010-04-29 |
| KR101214766B1 (ko) | 2012-12-24 |
| EP1427442A4 (en) | 2006-06-21 |
| WO2003061558A2 (en) | 2003-07-31 |
| EA006602B1 (ru) | 2006-02-24 |
| JP2005515237A (ja) | 2005-05-26 |
| CN1638794A (zh) | 2005-07-13 |
| US20060188518A1 (en) | 2006-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7449189B2 (en) | Glycoconjugate vaccines for use in immune-compromised populations | |
| Devi et al. | Antibodies to poly [(2----8)-alpha-N-acetylneuraminic acid] and poly [(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1. | |
| AU2005316864B2 (en) | Glycoconjugate vaccines containing peptidoglycan | |
| US6632437B1 (en) | Immunogenic polysaccharide-protein conjugates containing poly α(2→8), α(2→9) NeuNAc capsular polysaccharides | |
| EA037500B1 (ru) | Способы и композиции для иммунной защиты против внекишечной патогенной e. coli | |
| EP0549617A1 (en) | IMPROVED VACCINE COMPOSITION. | |
| EP3035957B1 (en) | A bacterial vaccine and methods for manufacture thereof | |
| EP4512419A1 (en) | Polyvalent pneumococcal polysaccharide conjugate vaccine component and application thereof | |
| Guttormsen et al. | Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching | |
| Cryz Jr et al. | Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines | |
| Robbins et al. | Haemophilus influenzae type b | |
| Abu-Baker et al. | Synthesis, characterization, and immunological properties of LPS-based vaccines composed of O-polysaccharides conjugated with recombinant exoprotein a from Pseudomonas aeruginosa | |
| AU2002365253B2 (en) | Glycoconjugate vaccines for use in immune-compromised populations | |
| Cross | Development of an anti-endotoxin vaccine for sepsis | |
| CN101443454A (zh) | 多价脑膜炎球菌衍生化的多糖-蛋白质缀合物和疫苗 | |
| AU2002365253A1 (en) | Glycoconjugate vaccines for use in immune-compromised populations | |
| NZ531647A (en) | Glycoconjugate vaccines for use in immune-compromised populations against Staphylococcal and Enterococcal infections | |
| Naso et al. | Polysaccharide conjugate vaccines for the prevention of gram-positive bacterial infections | |
| Lee | Capsule and vaccine development | |
| AU662141C (en) | Polysaccharide-protein conjugates | |
| Bhattacharjee et al. | Vaccines Against Bacterial Endotoxins | |
| Byrd | Development of conjugate vaccines to protect pigs against swine pleuropneumonia induced by Actinobacillus pleuropneumoniae |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GB | Transfer or rights |